Roger Tell
Technik-/Wissenschafts-/F&E-Leiter bei ISOFOL MEDICAL AB
Aktive Positionen von Roger Tell
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ISOFOL MEDICAL AB | Technik-/Wissenschafts-/F&E-Leiter | 01.02.2019 | - |
Vorstandsvorsitzender | 22.06.2023 | 09.01.2024 | |
VIVESTO AB | Direktor/Vorstandsmitglied | 25.05.2022 | - |
Karriereverlauf von Roger Tell
Ehemalige bekannte Positionen von Roger Tell
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Corporate Officer/Principal | - | 01.02.2019 |
Ausbildung von Roger Tell
Karolinska Institutet | Doctorate Degree |
Statistik
International
Schweden | 5 |
Operativ
Chief Executive Officer | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
ISOFOL MEDICAL AB | Health Technology |
VIVESTO AB | Health Technology |
Private Unternehmen | 1 |
---|---|
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
- Börse
- Insiders
- Roger Tell
- Erfahrung